Pulmonx Corporation provided earnings Guidance for 2023. For the period, the company is increasing its expectation for revenue to now range from $67 million to $68 million, which represents approximately 25% to 27% growth over the Company's fiscal year 2022 revenue. This updated guidance compares to prior 2023 revenue guidance of $64 million to $66 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.01 USD | -0.74% | -8.77% | -37.18% |
May. 01 | Earnings Flash (LUNG) PULMONX CORPORATION Posts Q1 Revenue $18.9M, vs. Street Est of $17.9M | MT |
May. 01 | Transcript : Pulmonx Corporation, Q1 2024 Earnings Call, May 01, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.18% | 311M | |
+75.56% | 12.56B | |
-23.35% | 7.47B | |
+8.51% | 6.75B | |
+14.95% | 5.5B | |
-15.58% | 4.94B | |
+30.59% | 4.66B | |
-25.47% | 3.75B | |
-22.61% | 2.92B | |
+49.50% | 2.4B |
- Stock Market
- Equities
- LUNG Stock
- News Pulmonx Corporation
- Pulmonx Corporation Provides Earnings Guidance for 2023